Clinical Trials Logo

Other clinical trials

View clinical trials related to Other.

Filter by:

NCT ID: NCT05693779 Withdrawn - Clinical trials for Chronic Thromboembolic Pulmonary Hypertension

Exercise Therapy After Pulmonary Thromboendarterectomy or Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension

EXPECT-PH
Start date: May 2023
Phase: N/A
Study type: Interventional

This study is being completed to determine the feasibility and acceptability of completing a home-based, structured, low-to-moderate intensity exercise training program in chronic thromboembolic pulmonary hypertension (CTEPH) patients following surgical or percutaneous intervention. Eligible participants will be enrolled and have a 12 week home based exercise training program. The study team hypothesizes that: The following percentage of participants successfully complete the ramp-up phase of the exercise program: - Greater or equal to 70% at end of week 7 - Greater or equal to 80% at end of week 10 - Greater or equal to 90% at end of week 12 - Greater or equal to 80% of participants will both complete ≥1 week of maintenance phase exercise and complete 12 weeks of the exercise intervention. - Patients will have no adverse events, defined as syncope, worsening World Health Organization (WHO) functional class, pulmonary hypertension (PH) related hospitalization, or death, caused by the exercise intervention.

NCT ID: NCT05667337 Withdrawn - Clinical trials for Corneal Inflammation

Open-label Prospective Clinical Trial Evaluating the Safety and Efficacy of Biosynthetic CLP-PEG-MPC Corneal Implants in Patients Undergoing High-risk Deep Anterior Lamellar Keratoplasty.

CLP-PEG-MPC
Start date: January 1, 2026
Phase: N/A
Study type: Interventional

This is an open-label and prospective clinical trial, in which a maximum of 5 eyes of 5 patients will receive a CLP-PEG-MPC synthetic cornea during deep anterior lamellar keratoplasty (DALK) surgery and will be followed up over 24 months.

NCT ID: NCT05647512 Withdrawn - Clinical trials for Relapsed or Refractory Multiple Myeloma

Study of LM-305 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) and Other Plasma Cell Diseases

Start date: January 18, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

A Phase I/II Study of LM-305 in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

NCT ID: NCT05643950 Withdrawn - Urinary Retention Clinical Trials

Effectiveness and Cost-effectiveness of the T-Control® Catheter in Patients With Acute Urine Retention

Start date: August 1, 2023
Phase: N/A
Study type: Interventional

The general purpose of this study is to assess the preliminary effectiveness and cost-effectiveness of the T-Control® catheter versus the Foley type catheter in patients with Acute Urine Retention.

NCT ID: NCT05641298 Withdrawn - Cystic Fibrosis Clinical Trials

Study to Determine the Efficacy&Safety of ARV-1801(ACG-701) for the Treatment of Cystic Fibrosis Pulmonary Exacerbations

REPRIEVE
Start date: February 10, 2023
Phase: Phase 2
Study type: Interventional

This study will evaluate the efficacy and safety of an oral ARV-1801(ACG-701) plus optimized background therapy (OBT) compared to oral placebo plus OBT, each administered for 14 days, in the treatment of participants with Cystic Fibrosis-related pulmonary exacerbations (PEx).

NCT ID: NCT05633758 Withdrawn - Clinical trials for Acute Decompensated Heart Failure

Metolazone As Early Add On Therapy For Acute Decompensated Heart Failure

MELT-HF
Start date: March 2014
Phase: Phase 2
Study type: Interventional

The primary objective of the study is to determine efficacy of metolazone as synergistic therapy with Lasix in patients with acute decompensated heart failure. This will be a multicenter double blinded randomized placebo- controlled pilot study of the addition of 5 mg of metolazone per day for 2 days compared to placebo in patients admitted with acute decompensated heart failure.

NCT ID: NCT05628545 Withdrawn - Clinical trials for Advanced Hepatocellular Carcinoma

Adoptive Treatment of Advanced Hepatocellular Carcinoma With Allogeneic γδ-T Cells

Start date: November 1, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

Brief Summary: In this study, effects of γδ T cells on Advanced hepatocyte carcinoma The goal of this clinical trial is to learn about effects of allogeneic γδ T therapy in advanced hepatocyte carcinoma patients. The main question it aims to answer is:Will advanced hepatocyte carcinoma patients be benefit from allogeneic γδ T therapy? Participants will received GDKM-100injection (allo-γδ T Cells) Infusion every two weeks.

NCT ID: NCT05613348 Withdrawn - Clinical trials for B-cell Acute Lymphoblastic Leukemia

CD19 CAR T-cell Target Relapsed/Refractory Acute B Cell Leukemia/Lymphoma

CAR19T2
Start date: December 1, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This study aims to evaluate the safety and efficacy of humanized Anti-CD19 Chimeric Antigen Receptor-T cell (CAR19T2 T cell) in children with refractory/relapsed B-cell acute lymphoblastic leukemia/lymphoma.

NCT ID: NCT05612984 Withdrawn - Preterm Labor Clinical Trials

Calcium Aspirin Multiple Micronutrients (CAMMS) to Reduce Preterm Birth

CAMMS
Start date: April 1, 2024
Phase: Phase 3
Study type: Interventional

This trial will evaluate the impact of an integrated intervention of daily maternal calcium, aspirin, and multiple micronutrients (CAMMS) compared to iron-folic acid (IFA) during pregnancy on preterm birth and other adverse birth outcomes. Both interventions will be delivered through existing antenatal service platforms using context-specific strategies informed by formative research incorporating human-centered design processes to achieve high acceptability and high adherence, in three low-income countries with diverse contexts: Burkina Faso, Pakistan, and Zimbabwe.

NCT ID: NCT05600556 Withdrawn - Clinical trials for Malignant Solid Neoplasm

Virtual Reality for the Improvement of Patients Understanding of Disease and Treatment (MRgRT)

Start date: June 1, 2024
Phase: N/A
Study type: Interventional

This clinical trial explores if using virtual reality (VR) headsets will help to improve patient understanding of their disease and decrease anxiety about treatment. Three-dimensional (3D) images may help the patient visualize their tumor and location better and therefore understand potential side effects. Visualizing a virtual representation of the magnetic resonance imaging (MRI) linear accelerator (Linac) may decrease treatment related anxiety.